Tuva Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
NY open-source healthcare claims data transformation platform serving 1,500+ practitioners at Oscar Health and MultiCare; YC W22 $6M Virtue-backed first health system-backed open-source data platform competing with Datavant for healthcare analytics engineering.
About
Tuva Health is a New York-based open-source healthcare data transformation company — backed by Y Combinator (W22) with $6 million raised including a $5 million seed round in December 2024 led by Virtue with Box Group, YC, and health technology angels, plus MultiCare Capital Partners (investment from MultiCare Health System making Tuva the first open-source data platform backed by a health system) in February 2025 — operating the Tuva Project, the world's first open-source healthcare data transformation platform that enables payers, providers, and pharmaceutical companies to convert raw claims and EHR datasets into analytics-ready data models through built-in normalization, quality testing, and clinical enrichment. Tuva serves 1,500+ healthcare data practitioners and 30+ partners including Oscar Health and MultiCare.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.